LLY is looking shaky, despite fundamental improvements from its weight-loss drug tirzepatide.
A couple bearish divergences indicate that the pace of the advance in the giant drugmaker's shares is slowing.
These recently downgraded names are displaying both quantitative and technical deterioration.
A bearish divergence can sometimes foreshadow a correction.
Traders have one of two choices to make here.
Here's where I think MRK can go and how to play it.
The growth crowd has moved on, leaving a stock trading at attractive levels.
Weakness in the broad market averages is likely to negatively impact the shares.
Recently poor sector performance is creating opportunity for long-term investors.
Here's our fresh take on the shares.